{"doi":"10.2147/cmar.s340719","title":"Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management","abstract":null,"journal":"Cancer Management and Research","year":2022,"id":616633,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1589901,"name":"Omar Abdel-Rahman","orcid":"0000-0002-5117-2502","position":1,"is_corresponding":false},{"id":1589899,"name":"Ali Fawaz","orcid":"0000-0001-6012-0221","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management","abstract":"<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) remains a significant worldwide health problem with a poor prognosis. A borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) is a tumor with limited vascular involvement that is technically resectable but with a high risk of positive margins (R1 resection).<h4>Objective</h4>To identify the current challenges that exist in the management of BR-PDAC.<h4>Methods</h4>A review of the literature was conducted to identify articles discussing the definitions and management of BR-PDAC.<h4>Key findings</h4>Several anatomic definitions of BR-PDAC exist, and there is significant heterogeneity in their utilization across published trials. To improve the odds of a margin negative (R0) resection, a neoadjuvant treatment approach involving chemotherapy with or without radiation is currently preferred. While supporting the efficacy of a neoadjuvant approach in BR-PDAC, the largest published randomized trials have utilized older gemcitabine-based regimens. Recently published Phase II evidence and meta-analyses have supported the use of modern multi-agent regimens such as FOLFIRINOX. The utility of adding radiation to a chemotherapy backbone remains in question. Due to remnant fibrosis and edema following neoadjuvant therapy, accurately selecting patients for resection based on a restaging CT scan is challenging. Furthermore, the role of adjuvant therapy in BR-PDAC patients receiving neoadjuvant therapy needs to be defined.<h4>Conclusion</h4>Though progress has been made, the optimal management of BR-PDAC is uncertain. Phase III trials utilizing modern chemotherapeutic regimens are needed to establish a standard of care.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36597515","pmcid":"PMC9805723","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=86428","host_type":"GOLD"},{"url":"https://www.dovepress.com/getfile.php?fileID=86428","host_type":"publisher"},{"url":"https://www.dovepress.com/borderline-resectable-pancreatic-cancer-challenges-for-clinical-manage-peer-reviewed-fulltext-article-CMAR","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9805723","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9805723","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9805723?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Medicine"],"mesh_terms":[],"keywords":["Surgery","Pancreatic cancer","Neoadjuvant chemotherapy","Borderline Resectable Disease"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T23:26:29.372617Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}